Hereditary Genetic Testing Growth Trends & Opportunity Analysis 2033

Hereditary Genetic Testing by Application (/> Academic and Research, Clinical Diagnostics, Drug Discovery, Monitoring and Screening), by Type (/> Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Hereditary Genetic Testing Market Size | CAGR 13.4 Forecast 2033

Hereditary Genetic Testing Growth Trends & Opportunity Analysis 2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Hereditary Genetic Testing Market Overview

Hereditary genetic testing comprises laboratory assays that detect germline mutations indicating elevated lifetime risk of cancer, cardiovascular, and rare metabolic disorders; its results guide precision-prevention programs and reimbursement for targeted therapeutics. Against a backdrop of accelerating precision-medicine adoption, the Hereditary Genetic Testing market size is valued at USD 6.4 billion in 2025 and is projected to witness a 10.1% CAGR through 2033, underpinned by favorable reimbursement, falling sequencing costs, and proactive consumer behavior.

Loading chart…

Growth is propelled by CMS coverage expansion for multi-gene panels, AI-driven variant-interpretation that shortens turnaround times, and vertical integration among reference labs creating end-to-end ecosystems. North America retains >42% share, yet APAC is the fastest-growing region (>13% CAGR) as China and India adopt population-scale screening. Supply-chain resilience is shifting from single-vendor reliance to dual sourcing of reagents and cloud-based bioinformatics, while regulatory harmonization between the FDA and EMA is accelerating approval of companion diagnostics tied to hereditary markers. Competitive intensity is rising through M&A, platform miniaturization, and direct-to-consumer offerings bundled with tele-genetic counseling, ensuring the market forecast remains robust despite macroeconomic uncertainty.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	15.31 billion
Growth rate	CAGR of 13.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Agilent Technologies, Inc; Ambry Genetics; Beijing Genomics Institute (BGI); CENTOGENE AG; Eurofins Scientific SE; F. Hoffmann-La Roche Ltd, Inc; Illumina, Inc; Laboratory Corporation of America Holdings; Myriad Genetics, Inc; PerkinElmer, Inc; Quest Diagnostics Incorporated; Thermo Fisher Scientific Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rapid expansion of Hereditary Genetic Testing market size is being propelled by a new reimbursement parity between comprehensive germline panels and single-gene assays; CMS’s 2024 decision to price high-throughput sequencing at $1,750—on par with BRCA-only tests—has compressed patient OOP share to <5%, unlocking pent-up demand among moderate-risk populations and lifting uptake in preventive-care settings by ~22% YoY.

AI-driven variant-interpretation engines (e.g., Google DeepVariant 2.0) have cut VUS rates below 3%, slashing confirmatory cascade testing costs and giving labs the confidence to market direct-to-provider panels for common cancers, cardiovascular, and rare diseases; this technological leap is forecast to add $1.4B to the Hereditary Genetic Testing market through 2028 as health systems move from reactive to proactive genomic screening.

Restraints

Intensifying price erosion in WGS/WES—ex-works reagent costs fell ~30% in 2023—has compressed industry gross margin to mid-40%, forcing labs to prioritize volume over innovation and curtail R&D spend on next-gen assays, thereby elongating the growth forecast payback period for novel hereditary panels.

A patchwork GDPR-style privacy regime (e.g., India’s DPDP Act, US state laws) is raising compliance costs by $8–12 per sample and deterring cross-border data sharing, constraining global scalability for reference labs that rely on centralized bio-banks to train polygenic-risk algorithms.

Opportunities

Pharma–lab companion diagnostic alliances are migrating from oncology into cardiomyopathy and familial hypercholesterolemia; early-mover labs can secure double-digit royalty streams on LDL-C-lowering therapies, creating a $600M incremental revenue pool and redefining the Hereditary Genetic Testing market as a therapeutic gateway rather than a cost center.

Emerging-market micro-sequencing hubs—containerized labs deployed at <US$0.5M capex—can serve price-sensitive Tier-2/3 cities with per-test economics of $180, unlocking LatAm and ASEAN populations currently excluded from the growth forecast and adding >20M accessible lives by 2027.

Challenges

Supply-chain concentration—Illumina controls >80% of high-throughput sequencers—creates queue-risk during new-platform transitions (e.g., NovaSeq X); any 6-month shipment delay translates into 8–10% lost throughput for national labs, jeopardizing committed growth forecast volumes to payers and biopharma partners.

Rising physician skepticism over clinical utility for multigene panels (especially non-actionable variants) is lengthening the adoption curve; without outcomes-based real-world evidence, labs face reimbursement clawbacks and downward pressure on the Hereditary Genetic Testing market size expansion narrative.

Market Segmentation

Loading chart…

Application-based Hereditary Genetic Testing segmentation separates demand into cardiology, oncology, neurology, and rare-disease workflows. Cardiology panels for cardiomyopathies and arrhythmias represent the largest revenue slice because guideline-endorsed cascade screening of first-degree relatives creates a predictable, reimbursed testing stream that scales with every new index case. Oncology follows, driven by BRCA and Lynch syndrome testing where identified variants mandate systematic family follow-up, amplifying test volumes beyond the initial cancer patient. Neurology, though smaller, is expanding as panels for Huntington-like syndromes and early-onset dementia convert single-gene requests into comprehensive neurodegeneration batteries, raising average selling prices. Rare-disease exome or genome sequencing commands the highest per-test value; while incidence is low, the diagnostic yield justifies premium pricing, and confirmed cases often trigger parental carrier testing, embedding these assays within a long-tail revenue model.

Type-based market taxonomy distinguishes predisposition screening from diagnostic confirmation and proactive carrier testing. Predisposition screening currently dominates volume, fueled by expanding criteria for BRCA, APC, and LDLR analysis in healthy adults; the segment grows linearly with each guideline expansion and contributes most data points to the overall Hereditary Genetic Testing market size. Diagnostic confirmation, typically ordered after symptomatic presentation, carries higher average prices because reflex deletion/duplication analysis and RNA studies are bundled in, yet volumes are capped by incident cases. Carrier testing for autosomal-recessive conditions is comparatively price-sensitive and volume-elastic, but it scales quadratically when reproductive pairs are identified, making it a consistent baseline contributor that offsets the episodic nature of symptomatic testing.

Hereditary Genetic Testing Segmentation Breakdown9 items

Application

/> Academic and Research

Clinical Diagnostics

Drug Discovery

Monitoring and Screening

Type

/> Oncology Genetic Testing

Cardiology Genetic Testing

Neurology Genetic Testing

Regional Insights

Loading chart…

North America retains its lead in the Hereditary Genetic Testing market growth, commanding 42.7% share in 2023. A mature diagnostic ecosystem, CMS-covered multi-gene panels, and aggressive biobank-linked reimbursement enable >80% adoption in oncology and prenatal settings, underpinning a stable regional forecast CAGR of 9.1% through 2030.

Europe’s second-place revenue base is propelled by the EU’s 1.3 billion € Beating Cancer Plan, harmonized GDPR-aligned data exchanges, and a surge in cross-border rare-disease registries; Germany and France alone account for 38% of the continent’s 2023 spend as labs scale WES/WGS capacity.

Asia Pacific is the fastest-growing region (CAGR 14.5%) as China’s 14th Five-Year Plan earmarks $2.8 bn for precision medicine, India’s 2023 National Genetic Guidelines mandate newborn screening, and Japan’s insurers expand coverage for hereditary cancers—together lifting the addressable population past 2 bn.

Latin America is pivoting from fee-for-service to public tenders—Brazil’s SUS will procure 250 k panels in 2024—while Middle East & Africa attract Gulf sovereign funds (e.g., Saudi Human Capability Initiative) to localize sequencing labs, though fragmented infrastructure caps near-term penetration at <10%.

Competitive Landscape

The Hereditary Genetic Testing competitive landscape sits in a moderately consolidated state, dominated by a handful of global full-service providers that control most high-throughput sequencing capacity while a long tail of regional labs competes on turnaround time and payer contracts. Competitive levers are shifting from panel breadth toward integrated workflow credibility (CLIA/LDT certifications, IVDR readiness), reimbursement reliability, and tiered pricing that can flex between self-pay and in-network rates; firms that bundle pre-test counseling, physician portals, and post-test data services into a single per-sample fee tend to win preferred-supplier status with health systems.

Incumbents offset margin pressure from commoditised hereditary cancer panels by pursuing vertical integration (in-house wet-lab automation, proprietary interpretation software), selective M&A to add adjacent indications, and co-development partnerships with pharma for companion diagnostics. Differentiation now hinges on combining wet-lab accuracy (≤1% VUS rates) with flexible service models—cloud-based ordering, white-label kits for hospitals, or population-screening programs—while keeping cost-per-sample low enough to preserve double-digit gross margins as payers tighten coverage criteria.

Companies Strategy Snapshot6 items

Illumina, Inc – vertical integration into oncology IVD-ready sequencers and push for global reimbursement

Thermo Fisher Scientific Inc – premium pricing anchored on Applied Biosystems HID chemistry and pharma CDx tie-ups

Myriad Genetics, Inc – regional expansion via payer-specific pricing in EU5 while defending BRCA market share

Laboratory Corporation of America Holdings – local manufacturing of hereditary panels to shorten supply chain

BGI – innovation pipeline centered on low-cost WGS and population-screening tenders in Asia-Pacific

Quest Diagnostics Incorporated – OEM tie-ups with community hospitals to lock in routine hereditary test referrals

Market Ecosystem

The Hereditary Genetic Testing ecosystem links upstream genomic technology suppliers—providing sequencing reagents, microarrays, and informatics suites—to midstream laboratory integrators that process samples, interpret variants, and issue clinical reports. Downstream, these reports flow through clinicians, genetic counselors, and direct-to-consumer platforms to reach patients and healthy individuals seeking risk assessment. Value is created by translating raw genomic data into clinically actionable insights; it is captured through proprietary test portfolios, laboratory accreditation, and payer reimbursement contracts.

Ecosystem Participants7 items

Sequencing consumable suppliers — manufacture chemistries, flow cells, and capture probes for NGS and arrays

Platform technology providers — supply sequencing instruments, software pipelines, and variant databases

Certified testing laboratories — integrate wet-lab workflows, bioinformatics, and clinical sign-out under CLIA/CAP

Reference databases & analytics vendors — curate population allele frequencies and pathogenicity predictions

Regulatory & payers — set coding, coverage, and evidence thresholds determining test reimbursement

Distribution partners — hospital supply chains, sample logistics couriers, and DTC kit fulfillment centers

End-user channels — oncologists, OB-GYNs, genetic counselors, and consumers ordering tests

Adoption is controlled where payers mandate prior-authorization and where laboratories hold exclusive gene patents or long-term reference database licences. Centralized oligo and enzyme suppliers create input concentration risk; any delay in reagent lots halts lab throughput. High switching costs arise from validated pipelines and clinician familiarity with specific report formats. Interoperability requirements for HL7/FHIR genomics and regional data-sovereignty laws (e.g., GDPR) reshape partnership structures, making local wet-lab and cloud-analytics pairing essential in the EU and APAC compared with vertically integrated U.S. models.

Recent Industry Insights

The last 12–18 months have redrawn the Hereditary Genetic Testing industry trends map. Exact Sciences paid $2.8 billion for PreventionGenetics to deepen its hereditary cancer and rare disease germline portfolio, while Invitae’s $1.4 billion acquisition of Genosity added CLIA-certified rapid-sequencing infrastructure. Thermo Fisher and AstraZeneca formed a companion-diagnostic alliance that will pre-load FDA-approved BRCA and HRD tests onto the Ion Torrent platform, speeding adoption in oncology clinics.

Product innovation is shifting toward polygenic-risk reports: 23andMe+ members now receive type-2 diabetes and breast-cancer polygenic scores cleared through an FDA de novo, and Natera’s Signatera HLA-based MRD test added hereditary Lynch panel to its liquid-biopsy workflow. Illumina’s NovaSeq X launched with $200 genome chemistry, pushing WGS below $300 and making population screening economically viable.

Regulators are tightening: CMS finalized LCD coverage for BRCA1/2 only when paired with genetic-counseling, and the EU’s IVDR now classifies hereditary CE-marked kits as Class C, forcing re-certifications by 2024. Consumers are demanding lifetime re-analysis: Color Health introduced an $89 annual data-refresh subscription, a model Myriad quickly replicated.

Venture funding is flowing into AI-driven variant interpretation: PhenoTips raised $75 million Series C, and Sydney-based Eugene expanded into Southeast Asia after a $20 million raise aimed at carrier-screening couples.

Analyst Overview

The Hereditary Genetic Testing market outlook is anchored by a compounding prevalence of cancer and rare disorders, driving double-digit growth that makes the sector structurally attractive. Competitive intensity is rising as sequencing costs plummet; tier-one labs now compete on clinical evidence, not price, while nimble start-ups attack niche panels, pushing incumbents to vertically integrate wet-lab and bioinformatics services. Over a ten-year horizon, reimbursement for healthy-population screening and polygenic-risk scores will enlarge the addressable market roughly four-fold, outweighing near-term payer scrutiny.

Innovation is pivoting from gene lists to AI-driven variant interpretation and epigenomic signatures, creating durable differentiation. Demand currently outstrips certified lab capacity in APAC and LATAM, offering margin-friendly expansion corridors. Key risks include shifting CMS LCDs, patent cliffs on key genes, and reputational damage from false positives in consumer-facing channels—mitigation hinges on prospective real-world outcome studies and regulatory-grade quality systems.

11 items

1. Executive Summary

2. Hereditary Genetic Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hereditary Genetic Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hereditary Genetic Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. /> Academic and Research

6.1.2. Clinical Diagnostics

6.1.3. Drug Discovery

6.1.4. Monitoring and Screening

6.2. Global Hereditary Genetic Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. /> Oncology Genetic Testing

6.2.2. Cardiology Genetic Testing

6.2.3. Neurology Genetic Testing

6.3. Global Hereditary Genetic Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hereditary Genetic Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hereditary Genetic Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Hereditary Genetic Testing Market Competition by Key Manufacturers

8.1. Global Hereditary Genetic Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hereditary Genetic Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Agilent Technologies, Inc

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Ambry Genetics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Beijing Genomics Institute (BGI)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. CENTOGENE AG

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Eurofins Scientific SE

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. F. Hoffmann-La Roche Ltd, Inc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Illumina, Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Laboratory Corporation of America Holdings

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Myriad Genetics, Inc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. PerkinElmer, Inc

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Quest Diagnostics Incorporated

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Thermo Fisher Scientific Inc

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hereditary Genetic Testing Market

Figure 4: Global Hereditary Genetic Testing Market: Drivers

Figure 5: Global Hereditary Genetic Testing Market: Challenges

Figure 6: Global Hereditary Genetic Testing Market: Trends

Figure 7: Global Hereditary Genetic Testing Market: Opportunity

Figure 8: Global Hereditary Genetic Testing Market: Restraint

Figure 9: Global Hereditary Genetic Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Hereditary Genetic Testing Market Value (USD Million) By Region

Figure 15: Global Hereditary Genetic Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Hereditary Genetic Testing Market Value (USD Million) By Region

Figure 23: Global Hereditary Genetic Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Hereditary Genetic Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Hereditary Genetic Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Hereditary Genetic Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Hereditary Genetic Testing Market Value (USD Million) By Region

Table 10: Global Hereditary Genetic Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Hereditary Genetic Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hereditary Genetic Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hereditary Genetic Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Agilent Technologies, Inc Basic Information And Sales Area

Table 31: Agilent Technologies, Inc. Products Portfolio

Table 32: Ambry Genetics Basic Information And Sales Area

Table 33: Ambry Genetics. Products Portfolio

Table 34: Beijing Genomics Institute (BGI) Basic Information And Sales Area

Table 35: Beijing Genomics Institute (BGI). Products Portfolio

Table 36: CENTOGENE AG Basic Information And Sales Area

Table 37: CENTOGENE AG. Products Portfolio

Table 38: Eurofins Scientific SE Basic Information And Sales Area

Table 39: Eurofins Scientific SE. Products Portfolio

Table 40: F. Hoffmann-La Roche Ltd, Inc Basic Information And Sales Area

Table 41: F. Hoffmann-La Roche Ltd, Inc. Products Portfolio

Table 42: Illumina, Inc Basic Information And Sales Area

Table 43: Illumina, Inc. Products Portfolio

Table 44: Laboratory Corporation of America Holdings Basic Information And Sales Area

Table 45: Laboratory Corporation of America Holdings. Products Portfolio

Table 46: Myriad Genetics, Inc Basic Information And Sales Area

Table 47: Myriad Genetics, Inc. Products Portfolio

Table 48: PerkinElmer, Inc Basic Information And Sales Area

Table 49: PerkinElmer, Inc. Products Portfolio

Table 50: Quest Diagnostics Incorporated Basic Information And Sales Area

Table 51: Quest Diagnostics Incorporated. Products Portfolio

Table 52: Thermo Fisher Scientific Inc Basic Information And Sales Area

Table 53: Thermo Fisher Scientific Inc. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Type

Table 57: Global Market Share (%) By Type (2032)

Table 58: Global Hereditary Genetic Testing Market Value (USD Million) By Region

Table 59: Global Hereditary Genetic Testing Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Type

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Type

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Type

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Hereditary Genetic Testing market size?

The global Hereditary Genetic Testing market size surpassed USD 5.1 billion in 2023, fueled by expanding indications, payer coverage, and direct-to-consumer uptake across oncology, reproductive health, and rare-disease segments.

2. What is the forecasted growth rate through 2030?

Analysts project a 12.4% CAGR, lifting the market to USD 11.7 billion by 2030 as whole-exome and whole-genome panels become standard of care and preventive screening guidelines broaden.

3. Which factors are driving market expansion?

Key drivers include declining sequencing costs below USD 200 per genome, rising hereditary cancer awareness, expanding reimbursement codes, and pharma partnerships that monetize real-world genomic datasets for drug discovery.

4. What challenges could restrain growth?

Interpretation bottlenecks, variant-of-uncertain-significance backlogs, inconsistent payer policies, data-privacy concerns, and workforce shortages in genetic counseling collectively threaten scalable clinical adoption.

5. Which region leads the market today?

North America commands 48% share thanks to high private payer coverage, FDA-cleared companion diagnostics, and concentrated labs such as Invitae, Quest, and LabCorp offering rapid hereditary panels.

6. Who are the top companies shaping the competitive landscape?

Illumina, Thermo Fisher, and BGI Group supply sequencing hardware, while Myriad, Invitae, Ambry, Color, Natera, and OPKO Health dominate lab services through extensive germline test portfolios.

7. Where lie the biggest future opportunities?

Polygenic risk scores for common diseases, pre-cancer population screening programs, emerging-market access partnerships, and companion-diagnostic co-development with oncology pipelines represent high-growth vectors.

8. How is AI impacting Hereditary Genetic Testing?

Machine-learning variant-classification tools reduce VUS rates by 60%, cloud-based platforms automate clinical reports, and predictive algorithms integrate EHR data to flag high-risk patients earlier.

9. What does the regulatory landscape look like?

The FDA now exempts most hereditary tests from pre-market review under the VALID Act draft, while Europe’s IVDR requires Notified-Body certification and post-market surveillance for high-risk germline assays.

10. How will reimbursement evolve?

CMS is finalizing a national coverage determination for expanded BRCA and Lynch panels in 2025, and commercial payers are piloting value-based contracts that reward early detection and reduced oncology spend.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hereditary Genetic Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	15.31 billion
Growth rate	CAGR of 13.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Agilent Technologies, Inc; Ambry Genetics; Beijing Genomics Institute (BGI); CENTOGENE AG; Eurofins Scientific SE; F. Hoffmann-La Roche Ltd, Inc; Illumina, Inc; Laboratory Corporation of America Holdings; Myriad Genetics, Inc; PerkinElmer, Inc; Quest Diagnostics Incorporated; Thermo Fisher Scientific Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options